AMETEK, Inc. Q2 2024 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2024. AMETEK, Inc. is a large accelerated filer operating in two primary reportable segments: Electronic Instruments Group (EIG) and Electromechanical Group (EMG). The company manufactures and distributes electronic instruments and electromechanical devices for industrial, aerospace, and commercial applications.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales | $1,734.8 million | $1,646.1 million | $3,471.0 million | $3,243.2 million |
| Operating Income | $447.5 million | $418.8 million | $864.7 million | $824.3 million |
| Net Income | $337.7 million | $324.2 million | $648.6 million | $630.0 million |
| Diluted EPS | $1.45 | $1.40 | $2.79 | $2.72 |
| Operating Margin | 25.8% | 25.4% | 24.9% | 25.4% |
| Free Cash Flow (YTD) | $742.6 million | $673.9 million | N/A | N/A |
| Total Debt (Net) | $2,651.4 million | N/A | N/A | N/A |
| Cash & Equivalents | $396.6 million | N/A | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2024 net sales increased 5.4% year-over-year, driven by an 8% contribution from acquisitions, partially offset by a 2% organic decline. YTD sales grew 7.0%.
- Profitability: Operating income reached a record $447.5 million in Q2. Segment operating margins improved to 27.3% in Q2 (up from 26.9% in Q2 2023), excluding the dilutive impact of recent acquisitions.
- Segment Performance:
- EIG: Sales up 1.7% and operating income up 13.9% due to acquisitions and Operational Excellence initiatives.
- EMG: Sales up 13.6% (record quarter) driven by acquisitions, but operating income fell 9.6% due to customer inventory normalization in automation businesses and dilutive acquisition impacts.
- Interest Expense: Increased 63.4% in Q2 to $30.6 million, primarily due to higher borrowings under the revolving credit facility to fund 2023 acquisitions.
- Backlog: Unfilled orders decreased 3.7% to $3,403.0 million as of June 30, 2024.
Guidance, Outlook, and Risks
- Outlook: Management expects customer inventory normalization in the EMG automation and engineered solutions businesses to continue through the remainder of 2024. The full-year impact of 2023 acquisitions and Operational Excellence initiatives is expected to remain positive.
- Dividends: The Board approved a 12% increase in the quarterly dividend to $0.28 per share, effective February 2024.
- Acquisition Integration: The company recorded $29.2 million in pre-tax integration costs related to the Paragon Medical acquisition in Q1 2024. Accounting for Paragon and Amplifier Research is still being finalized.
- Liquidity: The company maintains $2,483.2 million in available borrowing capacity. The debt-to-capital ratio improved to 22.3% from 27.5% at year-end 2023.
- Risks: Key risks include supply chain disruptions, international sales volatility, raw material costs, and the successful integration of future acquisitions.
Investor Verification Checklist
- Organic Growth: Verify the extent of the organic sales decline (-2% in Q2) and its persistence in the EMG segment due to customer inventory normalization.
- Acquisition Dilution: Assess the timeline for the 2023 acquisitions (UEI, Amplifier Research, Paragon) to become accretive to operating margins.
- Interest Costs: Monitor the trajectory of interest expense as the company pays down debt used for acquisitions.
- Backlog Trends: Track the backlog of unfilled orders, which declined 3.7% quarter-over-quarter, to gauge future revenue visibility.
- Integration Costs: Confirm if additional integration costs related to Paragon Medical will impact future quarters.